Study of Antiviral Activity of Recombinant Human Interleukin-7 with Various Experimental Models of Hepatitis C Viral Infection

Authors

  • Yulia I. Porva SI “L.V. Gromashevsky Institute of epidemiology and infectious diseases” of NAMS of Ukraine, Kyiv, Ukraine
  • Svitlana L. Rybalko SI “L.V. Gromashevsky Institute of epidemiology and infectious diseases” of NAMS of Ukraine, Kyiv, Ukraine
  • Svitlana T. Dyadyun SI “L.V. Gromashevsky Institute of epidemiology and infectious diseases” of NAMS of Ukraine, Kyiv, Ukraine
  • Tetiana M. Lutsenko UA “Pro-Pharma” LLC, Kyiv, Ukraine
  • Alexander Yu. Galkin Igor Sikorsky Kyiv Polytechnic Institute, Ukraine https://orcid.org/0000-0002-5309-6099
  • Yanina A. Poholenko Institute of molecular biology and genetics of NAS of Ukraine, Kyiv, Ukraine
  • Oksana B. Gorbatyuk Institute of molecular biology and genetics of NAS of Ukraine, Kyiv, Ukraine

DOI:

https://doi.org/10.20535/ibb.2017.1.1.112852

Keywords:

Human interleukin-7 recombinant, Hepatitis C virus, Antiviral activity, Viral load

Abstract

Background. Interleukin-7 (IL-7) is one of the most important regulatory cytokine of immune system. Given the ability of IL-7 to the modulation of T- and B-cell responses and T-cell homeostasis we may assume that IL-7 not only has the ability to influence the formation of specific immunity and immunodeficiency state, but also inhibit the reproduction of viruses, including hepatitis C virus (HCV).

Objective. Study of antiviral activity of recombinant human IL-7 (rIL-7) with experimental models of viral hepatitis C infection in vitro on sensitive virus epithelial and lymphoid cells.

Methods. We have used the following inoculated cell cultures: Jurkat, rat neurinoma of gasserian ganglion and bovine kidney. As used surrogate HCV we used virus of bovine diarrhea. To study the antiviral activity different concentrations of rIL-7 were injected into the cell culture, producing HCV, and determined virus load. Also we have performed cytological analysis of cells and determined its proliferative activity under influence of rIL-7.

Results. It has been shown that rIL-7 inhibits surrogate HCV reproduction in in vitro conditions (SS50 – 3 mg/ml, ED50 – 4.7 ng/ml, IS – 640). Highest proliferation of intact T-cells is determined at rIL-7 doses 0.3 mg/m and 0.025 mg/ml. rIL-7 affected HCV infected cells differently: during the first 3 days the number of cells decreased or did not change, and after 2–3 weeks the number of cells increased almost 2 times. When we injected rIL-7 with dose of 6 mg/ml within 3 days we obtained 89% viral inhibition at the 3rd day and 100 % at the 4th day; using the dose of rIL-7 0.3 mg/ml the inhibition on the 4th day was 100 %; using dose of rIL-7 1.5 mg/ml the inhibition settled at 55 % for 4 days.

Conclusions. As a result of the studies directed towards determining the effect of rIL-7 on surrogate HCV reproduction, HCV cDNA producing transfected human T-cells Jurkat, it was showed that rIL-7 effectively inhibits virus reproduction.

Author Biographies

Yulia I. Porva, SI “L.V. Gromashevsky Institute of epidemiology and infectious diseases” of NAMS of Ukraine, Kyiv

Senior researcher at the laboratory of experimental chemotherapy of viral infections

Svitlana L. Rybalko, SI “L.V. Gromashevsky Institute of epidemiology and infectious diseases” of NAMS of Ukraine, Kyiv

Professor, head of the laboratory of experimental chemotherapy of viral infections

Svitlana T. Dyadyun, SI “L.V. Gromashevsky Institute of epidemiology and infectious diseases” of NAMS of Ukraine, Kyiv

Senior researcher at the laboratory of experimental chemotherapy of viral infections

Tetiana M. Lutsenko, UA “Pro-Pharma” LLC, Kyiv

Head of the R&D group 

Alexander Yu. Galkin, Igor Sikorsky Kyiv Polytechnic Institute

Dr. sci., associate professor, assistant professor at the Industrial Biotechnology Department of Faculty of Biotechnology and Biotechnics

Yanina A. Poholenko, Institute of molecular biology and genetics of NAS of Ukraine, Kyiv

Junior researcher at the Department of cell regulatory mechanisms 

Oksana B. Gorbatyuk, Institute of molecular biology and genetics of NAS of Ukraine, Kyiv

Researcher at the Department of cell regulatory mechanisms

References

Fry TJ, Maskall CL. Interleukin-7: from bench to clinic. Blood. 2002 Jun 1;99(11):3892-3894. DOI 10.1182/blood.V99.11.3892

Bolotin E, Annett G, Parkman R, Weinberg K. Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant. 1999 Apr;23(8):783-8.

Rosenberg SA, Sportès C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother. 2006 May-Jun;29(3):313-9. DOI 10.1097/01.cji.0000210386.55951.c2

De Saint-Vis B, Fugier-Vivier I, Massacrier C, Gaillard C, Vanbervliet B, Aït-Yahia S, et al. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J Immunol. 1998 Feb 15;160(4):1666-76.

Sorg RV, McLellan AD, Hock BD, Fearnley DB, Hart DN. Human dendritic cells express functional interleukin-7. Immunobiology. 1998 Mar;198(5):514-26. DOI 10.1016/S0171-2985(98)80075-2

Clarke D, Katoh O, Gibbs RV, Griffiths SD, Gordon MY. Interaction of interleukin-7 (IL-7) with glycosaminoglycans and its biological relevance. Cytokine. 1995 May;7(4):325-30. DOI 10.1006/cyto.1995.0041

Kimura K, Matsubara H, Sogoh S, Kita Y, Sakata T, Nishitani Y, et al. Role of glycosaminoglycans in the regulation of T cell proliferation induced by thymic stroma-derived T cell growth factor. J Immunol. 1991 Apr 15;146(8):2618-24.

Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID), Nature. 1995 Sep 7;377(6544):65-8. DOI 10.1038/377065a0

Russell S, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science. 1995 Nov 3;270(5237):797-800.

Fry T, Mackall C. Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol. 2001 Oct;22(10):564-71.

Hardy R, Carmack CE, Shinton SA, Kemp JD, Hayakawa K. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J Exp Med. 1991 May 1;173(5):1213-25.

Morrissey PJ, Conlon P, Braddy S, Williams DE, Namen AE, Mochizuki DY. Administration of IL-7 to mice with cyclophosphamide-induced lymphopenia accelerates lymphocyte repopulation. J Immunol. 1991 Mar 1;146(5):1547-52.

Lynch D, Namen A, Miller R. In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti-tumor cytotoxic T lymphocytes. Eur J Immunol. 1991 Dec;21(12):2977-85. DOI 10.1002/eji.1830211212

Plumb AW, Patton DT, Seo JH, Loveday EK, Jean F, Ziegler SF, et al. Interleukin-7, but not thymic stromal lymphopoietin, plays a key role in the T cell response to influenza A virus. PLoS One. 2012;7(11):e50199. DOI 10.1371/journal.pone.0050199

Larrubia J, Lokhande MU, García-Garzón S, Miquel J, González-Praetorius A, Parra-Cid T, et al. Persistent hepatitis C virus (HCV) infection impairs HCV-specific cytotoxic T cell reactivity through Mcl-1/Bim imbalance due to CD127 down-regulation. J Viral Hepat. 2013 Feb;20(2):85-94. DOI 10.1111/j.1365-2893.2012.01618.x

Hou L, Jie Z, Desai M, Liang Y, Soong L, Wang T, et al. Early IL-7 production by intrahepatic T cell is important for adaptive immune responses in viral hepatitis. J Immunol. 2013 Jan 15;190(2):621-9. DOI 10.4049/jimmunol.1201970

Blumkin VN, Zhdanov VM. The impact of viruses on the chromosome apparatus and cell division. Moscow: Medicina; 1973. 128 p.

Published

2017-12-20

How to Cite

1.
Porva YI, Rybalko SL, Dyadyun ST, Lutsenko TM, Galkin AY, Poholenko YA, Gorbatyuk OB. Study of Antiviral Activity of Recombinant Human Interleukin-7 with Various Experimental Models of Hepatitis C Viral Infection. Innov Biosyst Bioeng [Internet]. 2017Dec.20 [cited 2024Nov.21];1(1):27-35. Available from: https://ibb.kpi.ua/article/view/112852

Issue

Section

Articles